New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy
PRESS RELEASE ER+ breast cancer patients reclassified as ER+ Read More
PRESS RELEASE ER+ breast cancer patients reclassified as ER+ Read More
PRESS RELEASE Simultaneous creation of Global Lab Center of Excellence Read More
PRESS RELEASE Determination finds that Agendia’s MammaPrint® Breast Cancer Risk Read More
PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Read More
PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Read More
PRESS RELEASE Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Read More
PRESS RELEASE Latest Results from the I-SPY 2 Trial at Read More
PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Read More
For the first time, early-stage breast cancer patients and their Read More
Dataset of up to 10,000 full genome profiles matched with Read More